Norbert Gattermann

Heinrich-Heine-Universität Düsseldorf, Düsseldorf, North Rhine-Westphalia, Germany

Are you Norbert Gattermann?

Claim your profile

Publications (249)1140.25 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Natural Killer cells are well known to mediate anti-leukemic responses in myeloid leukemia but their role in myelodysplastic syndromes is not well understood. Here, in a cohort of newly diagnosed patients (n=75), widespread structural and functional natural killer cell defects were identified. Firstly, one subgroup of patients (13%) had a selective deficiency of peripheral natural killer cells (count < 10/mm3 blood) with normal frequencies of T and natural killer-like T cells. Natural killer cell-deficient patients were predominantly found in high-risk subgroups and were significantly associated with poor prognosis. In the second subgroup, representing the majority of patients (76%), natural killer cells were present but exhibited poor cytotoxicity. The defect was strongly associated with reduced levels of perforin and granzyme B. Notably, natural killer cell function and arming of cytotoxic granules could be fully reconstituted by in vitro stimulation. Further phenotypic analysis of these patients revealed an immature natural killer cell compartment that was biased towards CD56bright cells. The residual CD56dim cells exhibited a significant increase of the unlicensed NKG2A-KIR- subset and a striking reduction in complexity of the KIR repertoire. Taken together, these results suggests that the widespread defects in natural killer cell function of myelodysplastic patients are mostly due to either unsuccessful or inefficient generation of mature, functionally competent natural killer cells, which might contribute to disease progression due to impaired immune surveillance. Copyright © 2015, Ferrata Storti Foundation.
    Haematologica 02/2015; DOI:10.3324/haematol.2014.118679 · 5.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Myelodysplastic syndromes (MDS) present with a normo- or hyperplastic bone marrow in most cases. We aimed at a characterization of patients with different types of cellularity. We assessed marrow cellularity both by histology and cytology in 1270 patients and analysed hematologic, cytogenetic, and prognostic parameters accordingly. The concordance of the assessment of cellularity differed dramatically between histology and cytology as only 36.5% were described as hypocellular by both methods (p<0.0005) (hypocellular 16.4%, normocellular 23.3%, hypercellular 60.3%). There were no major differences with regard to hematopoietic insufficiency. The presence of fibrosis was associated to hypercellular bone marrow. Median survival differed from 38 months in hypocellular, 42 months in normocellular and 25 months in hypercellular MDS (p<0.0005). AML progression rates were 33% for hypercellular MDS after 2 years, whereas hypo- and normocellular had a progression rate of 19% after 2 years (p=0.018). IPSS and IPSS-R were able to identify different risk groups within all three cellularity groups. Based on our data, hypocellular patients obviously do not present as a separate entity, as there were no striking differences with regard to cytogenetics and WHO types. Assessment of cellularity should be performed by histopathology. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    European Journal Of Haematology 01/2015; DOI:10.1111/ejh.12512 · 2.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In Europe, azacitidine is the only hypomethylating agent approved for the treatment of patients with int-2-/high-risk myelodysplastic syndromes, offering significantly improved survival compared with conventional care. However, not all patients treated with azacitidine respond to treatment, and the vast majority of responders subsequently relapse. Currently, no standard care regimens have been established for patients after failure of azacitidine. Here, we discuss treatment options after loss of response or progression on azacitidine. In addition, we briefly consider optimization of first-line treatment along with potential biomarkers for identifying and monitoring response during treatment with azacitidine.
    Leukemia Research 09/2014; DOI:10.1016/j.leukres.2014.09.008 · 2.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Since 2001, chronic myelomonocytic leukemia (CMML) is classified by the WHO as myeloproliferative/myelodysplastic neoplasm. Herein we tried to better describe CMML patients with regard to hematological characteristics and prognosis using data of the Duesseldorf registry. We created 6 CMML subgroups, by dividing dysplastic and proliferative CMML at the cut-off of white blood cell count of 13,000/μl and splitting these two groups into 3 subgroups: CMML 0 with <5% blasts (n = 101), CMML I with 5%-9% blasts (n = 204) and CMML II with 10%-19% blasts (n = 81). For comparison we included patients with RCMD, RAEB I and II. The newly created CMML 0 group had better prognosis than CMML I and II, median survival times were 31 months (ms), 19 ms and 13 ms, respectively (p < 0.001). Median survival times between the corresponding dysplastic and proliferative subgroups 0 and 1 differed significantly: CMML 0 dysplastic 48 ms and CMML 0 proliferative 17 ms (p = 0.03), CMML I dysplastic 29 ms and CMML I proliferative 15 ms (p = 0.008), CMML II dysplastic 17 ms and CMML II proliferative 10 ms (p = 0.09). Outcome of CMML patients worsens with increasing medullary blasts and when presenting as proliferative type. Therefore it is justified to separate CMML with <5% medullary blasts.
    Leukemia Research 09/2014; DOI:10.1016/j.leukres.2014.09.003 · 2.69 Impact Factor
  • Source
    David P. Steensma, Norbert Gattermann
    Bailli&egrave re s Best Practice and Research in Clinical Haematology 06/2014; DOI:10.1016/j.beha.2014.04.008 · 2.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fragestellung. Unser Ziel war die Beurteilung der Mikrovaskularisation und des antiangiogenetischen Effektes einer Thalidomidtherapie mittels dynamischer kontrastverstärkter MRT (d-MRT) bei unterschiedlichen hämatologischen Erkrankungen. Methodik. Bei 20 Normalpersonen, 20 Patienten mit Myelodysplastischen Syndromen (MDS), 10 Patienten mit Osteomyelofibrose (OMF) und 10 Patienten mit Multiplem Myelom (MM) wurde eine schnelle Gradientenechosequenz (Turbo fast low angle shot 2D) mit pumpengesteuerter Gd-DTPA-Applikation vor und bei 18 davon durchschnittlich 4,3 Monate nach Therapiebeginn mit Thalidomid durchgeführt. Zwei Perfusionsparameter (Amplitude und Austauschratenkonstante) wurden berechnet und es erfolgten ein statistischer Vergleich der Werte zwischen Probanden und Patienten sowie eine Korrelation der klinischen Verlaufsparameter der Patienten mit den d-MRT-Ergebnissen. Ergebnisse. Bei den Patienten wurden im Vergleich zu den Normalpersonen durchschnittlich höhere Amplituden (Normalpersonen 14,4±5,2; MDS 24,8±8,1; OMF 35,9±4,3; MM 23,4±3,6) und Austauschratenkonstanten (Normalpersonen 0,124±0,042; MDS 0,136±0,036; OMF 0,144±0,068; MM 0,131±0,034) gemessen. Bei 14 von 18 im Verlauf untersuchten Patienten konnte eine signifikante (p<0,005) Reduktion der Perfusionsparameter in der d-MRT unter Thalidomidtherapie nachgewiesen werden. Klinisch zeigten sämtliche dieser Patienten eine Krankheitsremission. Schlussfolgerungen. Bei den untersuchten hämatologischen Erkrankungen liegen im Vergleich zu Normalpersonen signifikant höhere d-MRT-Perfusionsparameter der Lendenwirbelsäule vor. Unter antiangiogenetischer Therapie mit Thalidomid kommt es im Falle eines Therapieansprechens zum Abfall dieser Werte. Purpose. The aim of the study was to measure microcirculation parameters by dynamic contrast-enhanced MRI (d-MRI) and to evaluate the anti-angiogentic effects during treatment with thalidomide in different hematologic malignancies. Methods. In 20 healthy normal persons, 20 patients with myelodysplastic syndromes (MDS), 10 patients with multiple myeloma (MM) and 10 with myelofibrosis (MF) a fast gradient echo sequence (Turbo fast low angle shot 2D) with a pump controlled bolus infusion of gadolinium-DTPA was performed before and in 18 of these after beginning (average of 4,3 months) of a thalidomide therapy. Two pharmacokinetic parameters – the amplitude and exchange-rate-constant – were calculated and a statistical comparison of these values between healthy persons and patients as well as a correlation with the clinical course was executed. Results. Compared with the normal controls the patients showed a higher amplitude (normal persons 14.4±5.2, MDS 24.8±8.1, MF 35.9±4.3, MM 23.4±3.6) and exchange-rate-constant (normal persons 0.124±0.042, MDS 0.136±0.036, MF 0.144±0.068, MM 0.131±0.034). In the d-MRI-follow-up examinations a significant (p<0.005) reduction of the amplitude and exchange rate constant values was evident in 14 of 18 patients undergoing a thalidomide therapy. Clinically all of these patients showed a therapy responding with complete or partial diseases remission. Conclusions. In patients with hematologic malignancies significantly higher d-MRI-microcirculation parameters of the lumbar spine can be demonstrated than in normal persons. During anti-angiogenetic treatment with thalidomide a decrease of these values was observed in case of a responding to therapy.
    Der Radiologe 03/2014; 42(3):222-230. DOI:10.1007/s00117-002-0721-6 · 0.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Myelodysplastic syndromes (MDS) are heterogeneous diseases of the hematopoietic stem cell, with a median age of 70 years at diagnosis. In this age it is likely to have comorbid diseases. The MDS-specific comorbidity index (MDS-CI) is an easy to use tool for assessing comorbidities in MDS patients. We herein examined if the MDS-CI adds independent prognostic information to the lately revised International Prognostic Scoring System (IPSS-R). Methods: We retrospectively analyzed 1161 patients from the Duesseldorf MDS-Registry according to the MDS-CI. The IPSS-R was available in 506 patients. Results: The most frequent diseases were cardiac diseases, which were even more frequent in male patients 42% vs. 30% in female patients (p<0.001), followed by solid tumors, third are pulmonary diseases 9% (11% in males vs. 6% in females (p=0.002)), fourth and fifth are renal and hepatic comorbidities, which showed no difference in distribution to gender. Overall, male patients had more comorbidities than female patients (p=0.001). The three MDS-CI risk groups differed in terms of survival (39 months (ms) vs. 24ms vs. 15ms, (p<0.001)). The MDS-CI was able to separate three groups within the IPSS-R low risk group, (92 ms vs. 63 ms vs. 36 ms, (p < 0.0001)). After lumping very low und low risk patients together (n=221) median survival times also differed significantly (98ms, 70ms and 45ms, respectively (p=0.005)). In the group consisting of intermediate, high and very high risk patients (n=285) corresponding median survival times differed significantly, (22ms, 21ms and 7ms, respectively (p=0.017)). The causes of death differed between the MDS-CI groups, as in the low risk group more patients died not disease related than in the high risk group. Conclusion The MDS-CI adds significantly independent prognostic information to the IPSS-R. Our data prompted us to make a call for assessing comorbidities prospectively in clinical day to day practice and particularly in clinical trials in order to find out if patients with relevant comorbidities benefit from earlier therapy and if it is reasonable not to treat patients with a high comorbidity score and finally to make MDS patient population better comparable.
    Haematologica 01/2014; 99(3). DOI:10.3324/haematol.2013.101055 · 5.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aberrant DNA methylation is frequently found in human malignancies including acute myeloid leukemia (AML). While most studies focus on later disease stages, the onset of aberrant DNA methylation events and their dynamics during leukemic progression are largely unknown.
    Genome Medicine 01/2014; 6(4):34. DOI:10.1186/gm551 · 4.94 Impact Factor
  • Source
    David P Steensma, Norbert Gattermann
    [Show abstract] [Hide abstract]
    ABSTRACT: Iron overload in MDS starts even before patients become red-blood cell transfusion dependent, because disease-associated ineffective erythropoiesis suppresses hepcidin production in the liver and thus causes unrestrained iron absorption in the duodenum. However, the main cause of iron overload is regular transfusion therapy, which in MDS is associated with a risk of unclear magnitude for iron-related complications. Iron deposition in tissues can now be detected with non-invasive techniques such as T2* MRI. Iron toxicity in MDS may not only depend on the degree of tissue iron accumulation but also on the extent of chronic exposure to non-transferrin-bound iron (NTBI), including labile plasma iron (LPI) and intracellular labile iron pools, which increase the level of oxidative stress. Iron chelation therapy (ICT) can rapidly lower NTBI and LPI and more slowly mobilizes tissue iron stores. Further studies, including the ongoing TELESTO controlled trial, will more clearly define the role of ICT in MDS, including any effect on specific morbidities or mortality in the MDS setting.
    Best practice & research. Clinical haematology 12/2013; 26(4):431-444. DOI:10.1016/j.beha.2013.09.009 · 3.13 Impact Factor
  • Ulrich Germing, Guido Kobbe, Rainer Haas, Norbert Gattermann
    [Show abstract] [Hide abstract]
    ABSTRACT: Myelodysplastic syndromes (MDS) are malignant stem-cell diseases that are usually diagnosed in elderly patients who present with anemia or, less commonly, bi- or pancytopenia. Their incidence in persons over age 80 is above 50 new cases per 100 000 persons per year. Their clinical course is highly variable. About one-quarter of all patients with MDS develop acute leukemia. The median survival time from the moment of diagnosis is about 30 months. We selectively searched the PubMed database for pertinent articles and guidelines from the years 2000-2013. We used the search term "myelodysplastic syndromes." MDS are diagnosed by cytology, with consideration of the degree of dysplasia and the percentage of blast cells in the blood and bone marrow, and on a cytogenetic basis, as recommended in the WHO classification. In particular, chromosomal analysis is necessary for prognostication. The Revised International Prognosis Scoring System (IPSS-R) enables more accurate prediction of the course of disease by dividing patients into a number of low- and highrisk groups. The median survival time ranges from a few months to many years. The approved treatments, aside from transfusion therapy, include iron depletion therapy for low-risk patients, lenalidomide for low-risk patients with a deletion on the long arm of chromosome 5, and 5-azacytidine for high-risk patients. High-risk patients up to age 70 who have no major accompanying illnesses should be offered allogenic stem-cell transplantation with curative intent. The cure rates range from 30% to 50%. Mucositis, hemorrhages, infections, and graft-versus-host diseases are the most common complications of this form of treatment. Myelodysplastic syndromes are treated on an individualized, riskadapted basis after precise diagnostic evaluation and after assessment of the prognosis. More studies are needed so that stage-adapted treatment can be improved still further.
    Deutsches Ärzteblatt International 11/2013; 110(46):783-90. DOI:10.3238/arztebl.2013.0783 · 3.61 Impact Factor
  • Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 11/2013; DOI:10.1038/leu.2013.325 · 10.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Myelodysplastic syndromes (MDS) is a disease of predominantly elderly patients with a median age of >70 yrs. However, data on the management of these patients outside of clinical trials are scarce. To assess patterns of MDS management in routine patient care with regard to the impact of age, we conducted a multicenter, representative survey of MDS health services in Germany. Data of 269 patients treated at 57 institutions were collected from preplanned chart reviews and were analyzed retrospectively. At diagnosis, median age was 70 yrs, 50% of patients had a Karnofsky index (KI) of 90%, and 12% had a comorbidity index ≥ 3 according to Sorror et al. (J Clin Oncol, 25, 2007, 4246). Cytogenetic analysis and International Prognostic Scoring System (IPSS) risk assessment were performed significantly less frequently in patients >75 yrs than in patients ≤75 yrs (P < 0.001 and P = 0.019). In bivariate analysis, potential predictors for performing IPSS risk assessment were age ≤75 yrs (y/n, P = 0.019), diagnosis at a university hospital (y/n, P = 0.001), WHO subtypes RCUD (y/n, P = 0.028), RARS (y/n, P = 0.002), or RAEB II (y/n, P = 0.037). Patients ≤75 yrs were more likely to receive active therapies (i.e., chemotherapy, immunomodulatory therapy, or epigenetic therapy) than patients >75 yrs (51% vs. 37%, P = 0.007). In bivariate analysis age ≤75 yrs (y/n, P = 0.007) was a significant predictor for active treatment with no correlation with the other predictors [IPSS risk score int-2 or high (y/n, P = 0.005), WHO subtypes RCUD (y/n, P < 0.001), RCMD (y/n, P = 0.003), RAEB II (y/n, P < 0.001), or CMML I (y/n, P = 0.020)]. This survey confirms the impact of age on the thoroughness of MDS diagnosis and the decision for active treatment. As cytogenetic analysis and risk assessment are essential for the choice of appropriate therapy, elderly patients in particular may not be receiving adequate treatment.
    European Journal Of Haematology 09/2013; 91(6). DOI:10.1111/ejh.12196 · 2.41 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Within the MDS work-package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the NIH Consensus Development Program. A systematic review of the literature was performed including indexed original papers, indexed reviews and educational papers, and abstracts of conference proceedings. Guidelines were developed based on a list of patient- and therapy-oriented questions, and recommendations were formulated and ranked according to the supporting level of evidence. MDS should be classified according to the 2008 WHO criteria. An accurate risk-assessment requires not only the evaluation of disease-related factors, but also of those related to extra-hematological comorbidity. The assessment of individual risk enables the identification of fit patients with a poor prognosis, who are candidates for up-front intensive treatments, primarily allogeneic stem cell transplantation. A high proportion of MDS patients are not eligible for potentially curative treatment because of advanced age and/or clinically relevant comorbidities and poor performance status. In these patients, the therapeutic intervention is aimed at preventing cytopenia-related morbidity and preserving quality of life. A number of new agents are being developed, for which the available evidence is not sufficient to recommend routine use. The inclusion of patients into prospective clinical trials is strongly recommended.
    Blood 08/2013; 122(17). DOI:10.1182/blood-2013-03-492884 · 9.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients with myelodysplastic syndromes (MDS) often show elevated serum ferritin levels at diagnosis, probably caused by increased intestinal iron uptake attributable to ineffective erythropoiesis. Many patients also develop transfusional iron overload. Hepcidin, a pivotal regulator of iron homeostasis, controls iron uptake in the duodenum as well as iron release from macrophages and is potentially involved in iron distribution to different organs. We measured serum hepcidin, together with other laboratory parameters related to iron metabolism and hematopoiesis (ferritin, transferrin, transferrin saturation, soluble transferrin receptor, erythropoietin, and hemoglobin), and C-reactive protein as marker of inflammation, in 89 MDS patients. Hepcidin levels were measured with two different competitive ELISAs: (a) EIA-4705 as described by Schwarz et al. (J Gastroenterol 46:648-656; 2011) and (b) Hepcidin 25 bioactive ELISA (EIA-5258), which was develop by DRG Diagnostics, Marburg, in 2012. Median hepcidin levels with EIA-5258 were as follows: entire cohort 17.5 ng/ml (n = 89), RA/RARS 5.9 ng/ml (n = 5), RCMD 17.8 ng/ml (n = 38), RS-RCMD 8.7 ng/ml (n = 7), RAEB I/II 29.1 ng/ml (n = 22), CMML I/II 16.9 ng/ml (n = 10), and MDS with del(5q) 26.3 ng/ml (n = 7). Hepcidin levels of the RA/RARS patients were significantly lower than in the other groups except RS-RCMD. RS-RCMD had significantly lower levels than RAEB and 5q- patients. There was a positive correlation between hepcidin levels and serum ferritin and transferrin saturation, and a negative correlation between hepcidin and hemoglobin and transferrin. Malcovati et al. (Blood 112:2676a, 2008), Santini et al. (PLoS One 6:e23109, 2011), and Ambaglio et al. (Haematologica 98:420-423, 2013), using mass spectrometry, reported similar results. We further assessed transfusional status and could show that patients who had been transfused have significantly higher hepcidin levels (median 33.3 versus 8.8 ng/ml (p < 0.001)). A dichotomized hepcidin level correlated with worse survival. EIA-4705 as described by Schwarz showed no correlation with markers of iron metabolism. Measurement of serum hepcidin with an improved ELISA yield results that correlate with other parameters of iron metabolism as well as survival and transfusion needs.
    Annals of Hematology 07/2013; 92(12). DOI:10.1007/s00277-013-1839-5 · 2.40 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ineffective hematopoiesis is a major characteristic of MDS causing relevant morbidity and mortality. Mesenchymal stromal cells (MSC) have been shown to physiologically support hematopoiesis, but their contribution to the pathogenesis of MDS remains elusive. We show that MSC from patients across all MDS subtypes (n=106) exhibit significantly reduced growth and proliferative capacities accompanied by premature replicative senescence. Osteogenic differentiation was significantly reduced in MDS-derived MSC indicated by cytochemical stainings and reduced expression of Osterix and Osteocalcin. This was associated with specific methylation patterns which clearly separated MDS-MSC from healthy controls and showed a strong enrichment for biological processes associated with cellular phenotypes and transcriptional regulation. Furthermore, in MDS-MSC we detected altered expression of key molecules involved in the interaction with hematopoietic stem and progenitor cells (HSPC), in particular Osteopontin, Jagged1, Kit-ligand and Angiopoietin as well as several chemokines. Functionally, this translated into a significantly diminished ability of MDS-derived MSC to support CD34+ HSPC in LTC-IC assays associated with a reduced cell cycle activity. Taken together, our comprehensive analysis shows that MSC from all MDS subtypes are structurally, epigenetically and functionally altered, which leads to impaired stromal support and seems to contribute to deficient hematopoiesis in MDS.Leukemia accepted article preview online, 25 June 2013; doi:10.1038/leu.2013.193.
    Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 06/2013; DOI:10.1038/leu.2013.193 · 10.16 Impact Factor
  • Source
    Leukemia Research 05/2013; 37:S44. DOI:10.1016/S0145-2126(13)70098-5 · 2.69 Impact Factor
  • Source
    Leukemia Research 05/2013; 37:S106. DOI:10.1016/S0145-2126(13)70231-5 · 2.69 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose was to assess predictive factors for outcome in patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP) treated with nilotinib after imatinib failure. Imatinib-resistant and -intolerant patients with CML-CP (n=321) were treated with nilotinib 400 mg twice daily. Of 19 baseline patient and disease characteristics and two response end points analyzed, 10 independent prognostic factors were associated with progression-free survival (PFS). In the multivariate analysis, major cytogenetic response (MCyR) within 12 months, baseline hemoglobin 120 g/l, baseline basophils <4%, and absence of baseline mutations with low sensitivity to nilotinib were associated with PFS. A prognostic score was created to stratify patients into five groups (best group: 0 of 3 unfavorable risk factors and MCyR by 12 months; worst group: 3 of 3 unfavorable risk factors and no MCyR by 12 months). Estimated 24-month PFS rates were 90%, 79%, 67% and 37% for patients with prognostic scores of 0, 1, 2 and 3, respectively, (no patients with score of 4). Even in the presence of poor disease characteristics, nilotinib provided significant clinical benefit in patients with imatinib-resistant or -intolerant CML. This system may yield insight on the prognosis of patients.Leukemia advance online publication, 23 November 2012; doi:10.1038/leu.2012.305.
    Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 11/2012; 27(4). DOI:10.1038/leu.2012.305 · 10.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In 2008, the WHO proposed changes in the classification of MDS regarding RCUD and MDS unclassifiable. We validated these proposals by using 2032 patients of the Düsseldorf MDS Registry. 10% of the patients had RCUD and 6% MDS-U. Among patients with RCUD, only 9% had RN and 6% had RT. There was no correlation between dysplastic cell line and type of cytopenia. There was no difference in prognosis between RCMD and MDS-U and between RA, RT, and RN. The separation of RA, RN, and RT is not justified suggesting a consolidation as RCUD. MDS-U should be integrated into RCMD.
    Leukemia research 10/2012; 37(1). DOI:10.1016/j.leukres.2012.09.021 · 2.36 Impact Factor
  • Norbert Gattermann
    Blood 10/2012; 120(16):3167-8. DOI:10.1182/blood-2012-08-447094 · 9.78 Impact Factor

Publication Stats

9k Citations
1,140.25 Total Impact Points

Top Journals


  • 1994–2015
    • Heinrich-Heine-Universität Düsseldorf
      • • Klinik für Hämatologie, Onkologie und Klinische Immunologie
      • • Faculty of Medicine
      • • Institut für Biochemie
      Düsseldorf, North Rhine-Westphalia, Germany
  • 2003–2014
    • Universitätsklinikum Düsseldorf
      • Klinik für Hämatologie, Onkologie und Klinische Immunologie
      Düsseldorf, North Rhine-Westphalia, Germany
  • 2009–2010
    • King's College London
      Londinium, England, United Kingdom
    • Medizinische Universität Wien
      • Institut für Sozialmedizin
      Vienna, Vienna, Austria
  • 2007
    • Universität Ulm
      Ulm, Baden-Württemberg, Germany
    • University of Cologne
      Köln, North Rhine-Westphalia, Germany